Exits

Name Description Event Datesort icon Acquired By
Red Rock Biofuels Pioneer in renewable biofuels. Acquired 2016 <a href="http://www.jouleunlimited.com/" target="_blank">Joule Unlimited</a>
Editas Medicine Leading genome editing company translating its proprietary technology into novel solutions to treat a broad range of genetically-driven diseases. IPO 2016
Celexion LLC Developed powerful platform technologies. Acquired 2015 <a href="http://www.agenusbio.com/" target="_blank">Agenus</a>
Seahorse Bioscience, Inc. XF instruments are the industry standard in cellular bioenergetic measurements. Acquired 2015 <a href="http://www.agilent.com/home" target="_blank">Agilent Technologies</a>
Seres Therapeutics Developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. IPO 2015
<a href="http://www.affinnova.com/" target="_blank">Affinnova, Inc.</a> Improving innovation and marketing success rates. Acquired 2014 <a href="http://www.nielsen.com/us/en.html" target="_blank">Nielsen</a>
<a href="http://www.concertpharma.com" target="_blank">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. IPO 2014
<a href="http://www.regi.com/" target="_blank">LS9</a> Leading renewable chemical technology developer. Acquired 2014
<a href="http://www.t2biosystems.com/" target="_blank">T2 Biosystems, Inc.</a> Developing innovative diagnostic products to improve patient health. IPO 2014
<a href="http://www.agios.com/" target="_blank">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. IPO 2013
<a href="http://www.receptos.com/" target="_blank">Receptos, Inc.</a> Developing therapeutic candidates for the treatment of immune and metabolic diseases. IPO 2013
<a href="http://tphase.com/home" target="_blank">Tetraphase Pharmaceuticals, Inc.</a> Creating novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections. IPO 2013
<a href="http://www.shire.com/shireplc/en/home" target="_blank">Pervasis Therapeutics, Inc.</a> Developing novel therapeutics to promote vascular repair. Acquired 2012 <a href="http://www.shire.com/shireplc/en/home" target="_blank">Shire</a>
<a href="http://www.bdbiosciences.com/instruments/accuri/" target="_blank">Accuri Cytometers, Inc.</a> Developing and manufacturing revolutionary, low-cost, high-performance flow cytometers for researchers. Acquired 2011 <a href="http://www.bdbiosciences.com/instruments/accuri/" target="_blank">Becton, Dickinson and Company</a>
<a href="http://www.auventx.com/" target="_blank">Resolvyx Pharmaceuticals, Inc.</a> Developing resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Acquired 2011 <a href="http://www.celtictherapeutics.com/" target="_blank">Celtic Therapeutics</a>
<a href="http://www.aveopharma.com" target="_blank">AVEO Pharmaceuticals, Inc.</a> Discovering, developing and commercializing cancer therapeutics. IPO 2010
<a href="http://www.perkinelmer.com/" target="_blank">VisEn Medical, Inc.</a> Pioneering a new era of in vivo imaging. Acquired 2010 <a href="http://www.perkinelmer.com" target="_blank">PerkinElmer</a>
<a href="http://www.gilead.com/" target="_blank">CGI Pharmaceuticals, Inc.</a> Developing small molecule therapeutics for multiple oncology and immunology-based indications Acquired 2010 <a href="http://www.gilead.com/" target="_blank">Gilead</a>
<a href="http://www.covidien.com" target="_blank">Aspect Medical Systems, Inc.</a> Pioneer and global market leader in brain monitoring and measurement products Acquired 2010 <a href="http://www.covidien.com" target="_blank">Covidien</a>
<a href="http://www.millipore.com" target="_blank">Epitome Biosystems</a> Developing novel protein measurement systems based on Protien Epitope Tag technology Acquired 2009 <a href="http://www.millipore.com" target="_blank">Millipore</a>